... or a combination of carboplatin and paclitaxel.
Over 22 months of follow-up, the researchers found that gefitinib was more tolerable and resulted in a greater likelihood of response.
"We have ...
The targeted therapy gefitinib should be considered a first-line therapy for nonsmoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a ...
Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific ...
... . While the study led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer ( ...
HOUSTON, May 20 (UPI) -- A U.S. study shows Gefitinib, a once-promising drug for treating lung cancer, can enhance hormonal therapy for treating some metastatic breast cancers.
... (Herceptin) in the treatment of HER-2–positive breast cancer; $1,800 per month for gefitinib (Iressa) for the treatment of lung cancer; and more than $8,000 for a 6-day course of palifermin (Kepivance ...
... EGFR mutant and MET amplified non-small cell lung cancer tumours that were made resistant to gefitinib.
"Neither agent was effective alone, but tumour regression occurred in all animals when they ...
... factors have been shown to predict long-term outcome and tumor responses when taking erlotinib and gefitinib – common EGFR inhibitor drugs.
Previous studies have determined that ethnicity can have an ...
This press release is available in Spanish. HOUSTON - Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as ...
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of nonsmall cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease ...
... said Ulrike Heberlein of the University of California, San Francisco, noting that erlotinib and gefitinib, along with other EGFR inhibitors, not only cross the blood-brain barrier in humans, but they ...
... cancer in both never-smokers and smokers, including those with tumors resistant to targeted drugs such as gefitinib.
The study examined lung tumors from people who had never smoked and found high ...
